Paclitaxel liposomal - Aphios
Alternative Names: Liposome encapsulated paclitaxel - Aphios; Phospholipid nanosomes; TaxosomesLatest Information Update: 15 Jan 2022
At a glance
- Originator Aphios Corporation
- Class Albumins; Antineoplastics; Diterpenes; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes; Vascular disorder therapies
- Mechanism of Action Tubulin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (IV)
- 18 Jan 2011 Aphios' paclitaxel liposomal is available for licensing as of 18 Jan 2011. http://www.aphios.com
- 22 Jun 2009 Paclitaxel liposomal is still in preclinical trials for Breast and ovarian cancers in USA